Illumina Inc. and NashBio Celebrate Milestone in Genomic Research

In a significant advancement for the field of genomics and drug discovery, Illumina Inc. (NASDAQ: ILMN) and Nashville Biosciences, LLC (NashBio) announced on March 19, 2025, that their collaborative initiative, the Alliance for Genomic Discovery (AGD), has successfully sequenced 250,000 whole genomes. This remarkable achievement positions AGD as one of the largest and most comprehensive clinical genomic datasets globally, paving the way for accelerated drug target discovery and therapeutic development.

The AGD initiative brings together a consortium of leading biotech and biopharma organizations, aiming to leverage the rich genomic data for transformative breakthroughs in therapeutic research. Todd Christian, Senior Vice President of Services, Arrays, and Genomic Access at Illumina, expressed enthusiasm about the project's impact, stating, “AGD is delivering on its promise of unlocking new discoveries...the rapid achievement of this major milestone demonstrates the value of our strategic collaborations across the ecosystem.”

The dataset, which includes de-identified DNA samples sourced from Vanderbilt University Medical Center (VUMC)'s BioVU® biobank, has already begun yielding significant findings. According to Kári Stefánsson, CEO of deCODE genetics, one of the biopharma members, the AGD dataset is unique for its diversity and depth, enabling discoveries that would otherwise remain elusive.

A recent study published in *Nature* highlights the importance of genetic evidence in drug development, indicating that drugs with a genetic basis are 2.6 times more likely to succeed compared to those without. This statistic underscores the critical role that the AGD dataset will play in shaping the future of drug discovery, particularly in addressing complex diseases such as autoimmune disorders and liver fibrosis.

Looking ahead, the AGD initiative plans to expand its genomic dataset further by incorporating multiomic layers. Leeland Ekstrom, CEO of NashBio, noted the extensive interest from AGD members and the broader market in exploring additional omics modalities, including proteomics. This next phase aims to deepen the understanding of disease mechanisms and enhance the identification of pharmacological targets.

Illumina's commitment to innovation is evident as the company unveils a roadmap of advancements that will establish the industry’s largest portfolio of omics solutions. This includes innovations across genomics, spatial transcriptomics, single-cell analysis, CRISPR technologies, and more, all of which are set to enrich the AGD dataset and drive deeper biological insights.

Since launching in January 2023, the AGD project has demonstrated unprecedented speed, completing its sequencing goal in just two years. This is a remarkable feat considering that similar initiatives have historically required three to five years to accomplish half the number of whole genomes. The collaborative nature of the AGD and its member organizations has been instrumental in achieving this rapid progress, setting a new standard for large-scale genomic projects.

The announcement of the completion of 250,000 whole genomes by Illumina and NashBio marks a pivotal moment in the field of genomics. With its vast dataset, the Alliance for Genomic Discovery aims to revolutionize drug discovery and therapeutic development, ultimately improving patient outcomes through enhanced genetic research. As the initiative looks to the future, the integration of multiomics promises to unlock even greater discoveries, solidifying AGD's role as a leader in genomic innovation.